Brain Health Devices Market, By Device Type (Magnetic Resonance Imaging, Magneto Encephalogram, Computed Tomography, Transcranial Doppler Device, Others), By Application (Stroke, Dementia, Epilepsy, Dyslexia, Others), By End User (Hospitals, Specialty Clinics, Research Institutes, Home Healthcare, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2024

Code : CMI1095

Pages :173

Formats :

Excel and PDF

Industry : Medical Devices

Key Developments

In September 2023, NTT Communications Corporation (NTT Com), part of the NTT group focusing on ICT solutions and international communications, has introduced a trial for "Brain Health Check Plus", a service using AI to detect early cognitive decline signs. The trial, which started on September 21, 2023, aligns with World Alzheimer's Day and aims to reduce the impact of dementia on individuals, families, and businesses by offering a fee-based navigation service.
In November 2022, Neurosteer Inc. received FDA clearance for its Neurosteer single-channel EEG brain monitoring platform. This clearance allows the versatile system to be used across various clinical environments. The platform provides continuous brain monitoring in intensive care units (ICUs) for critical interventions and facilitates early detection of pre-symptomatic cognitive decline, including Alzheimer's, Parkinson's, and dementia, within a physician's office. It supports rapid and cost-effective screening of individuals potentially affected by neurodegenerative disorders in pharmaceutical drug trials.
In February 2022, Masimo obtained USFDA clearance for its SedLine brain function monitoring system for pediatric patients aged 1-17 years, along with the SedLine Pediatric EEG Sensor. This clearance extends the benefits of SedLine to all patients one year old and above in the United States.
In April 2021, NeuraMetrix has been chosen by Boston University (BU) School of Medicine to contribute its innovative digital biomarker for detecting and monitoring brain diseases as part of BU's Precision Brain Health Initiative.